Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of product candidates to treat central nervous system disorders. Its lead product candidate roluperidone is in a confirmatory Phase 3 clinical trial for negative symptoms of schizophrenia. The company specializes in clinical trial design with endpoints linked directly to patient benefit in CNS conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -3.3 | — |
| Q3 2025 | 0 | — | -2.7 | — |
| Q4 2025 | 0 | — | -283.7 | — |
| Q1 2026 | 0 | — | -125.4 | — |
| Q2 2026 | 0 | — | 16.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Capstone Energy+, Inc. (CEPL), Energy Services of America Corporation (ESOA), Lifetime Brands, Inc. (LCUT), Patriot Acquisition Corp. (PTAC), Neuronetics, Inc. (STIM), Kolibri Global Energy Inc. (KGEI)